Boehringer kickstarts two Phase III trials as MASH therapy wins breakthrough status [Yahoo! Finance]
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: Yahoo! Finance
Concurrently, the company also started two Phase III trials, LIVERAGE and LIVERAGE-Cirrhosis, evaluating the therapy in patients with MASH with associated moderate or advanced fibrosis and cirrhosis, respectively. The FDA issues breakthrough designations to expedite certain therapies' evaluation and review processes based on early clinical evidence. The MASH therapies have seen an increased interest in recent months. In March, the FDA approved the first-ever MASH therapy, Madrigal Pharmaceuticals' Rezdiffra (resmetirom). GlobalData estimates the MASH market to reach sales of $25.7bn in 2032 across the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan). GlobalData is the parent company of Pharmaceutical Technology Survodutide is a dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors. In 2011, Boehringer licensed the therapy from Zealand Pharma. The companies first developed survodutide as a treatment for type 2 diabetes and obesity .
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Profit Outlook [Yahoo! Finance]Yahoo! Finance
- 3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move [Yahoo! Finance]Yahoo! Finance
- Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy? [Yahoo! Finance]Yahoo! Finance
- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Wall Street Analysts Believe Madrigal (MDGL) Could Rally 26.44%: Here's is How to Trade [Yahoo! Finance]Yahoo! Finance